Medicalgorithmics, a medtech company listed on the sWIG80 index, has entered into an agreement with one of the top three cardiac monitoring technology solution providers in the U.S. The new partner is a NASDAQ-listed entity. The agreement focuses on integrating Medicalgorithmics’ artificial intelligence system and diagnostic software with the partner’s heart monitoring equipment.
Medicalgorithmics, a medtech company included in the sWIG80 index, has signed a letter of intent with Diagnostyka Group – the leader in medical diagnostics in Poland – regarding the use of VCAST technology for coronary artery disease examinations. VCAST technology is based on artificial intelligence and is being developed by Kardiolytics, a subsidiary of Medicalgorithmics.
Medicalgorithmics Partners with US IDTF to Provide Software, AI Driven Analytics, and Monitoring Hardware
Medicalgorithmics, SA, a global leader in arrythmia monitoring software and AI-driven analytics, is pleased to announce it entered a definitive agreement to provide a burgeoning independent diagnostic and testing facility (IDTF) based in the southwestern United States with software, AI-driven analytics, and heart monitoring devices.
Medicalgorithmics, a cardiac medtech listed on the sWIG80 index, has achieved another milestone by initiating the CE certification process for its VCAST technology, designed for non-invasive diagnosis of coronary artery disease on coronary CT scans. The AI-based VCAST technology is being developed by Kardiolytics Inc., a subsidiary of Medicalgorithmics.